Heat shock protein antagonists in early stage clinical trials for NSCLC

References

• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394. Epub 2013/06/04.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Young JC, Agashe VR, Siegers K, et al. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol. 2004;5:781–791.
   PubMed Web of Science ®Google Scholar
• Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 2004;3:1021–1030.
   PubMed Web of Science ®Google Scholar
• Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene. 2003;22:9041–9047.
   PubMed Web of Science ®Google Scholar
• Ochiana S, Taldone T, Ciosis G. Designing drugs against Hsp90 for cancer therapy. New York (NY): Springer; 2014.
   Google Scholar
• Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18:64–76.
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10:86–103. .
   PubMed Web of Science ®Google Scholar
• Wang X, Chen M, Zhou J, et al. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J Oncol. 2014;45:18–30. .
   PubMed Web of Science ®Google Scholar
• Acunzo J, Katsogiannou M, Rocchi P. Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell Biol. 2012;44:1622–1631.
   PubMed Web of Science ®Google Scholar
• Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012;11:475–484.
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407–410.
   PubMed Web of Science ®Google Scholar
• Ko JC, Chen HJ, Huang YC, et al. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells. Regul Toxicol Pharmacol. 2012;64:415–424.
   PubMed Web of Science ®Google Scholar
• O’Connell BC, O’Callaghan K, Tillotson B, et al. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer. PLoS One. 2014;9:e115228.
   Google Scholar
• Proia DA, Sang J, He S, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 2012;30:2201–2209.
   PubMed Web of Science ®Google Scholar
• Zhang S, Hu Y, Huang Y, et al. Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer. Oncol Lett. 2015;9:2572–2576.
   PubMed Web of Science ®Google Scholar
• Lelj-Garolla B, Kumano M, Beraldi E, et al. Hsp27 Inhibition with OGX-427 sensitizes non-small cell lung cancer cells to erlotinib and chemotherapy. Mol Cancer Ther. 2015;14:1107–1116.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Stoller RG, Egorin M, et al. A phase 1b trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. J Clin Oncol. 2009;27:15s. Suppl, ASCO abstract 3547.
   PubMed Web of Science ®Google Scholar
• Infinity Pharmaceuticals I. Infinity reports topline data from phase 2 study of retaspimycin hydrochloride, Its Hsp90 inhibitor, in patients with non-small cell lung cancer 2013. [cited 2016 Oct 27]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1857866&highlight=
   Google Scholar
• Sessa C, Shapiro GI, Bhalla KN, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013;19:3671–3680.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013;13:152.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncology. 2015;26:1741–1748.
   PubMed Web of Science ®Google Scholar
• Pillai R, Fennell D, Kovcin V, et al. Phase 3 study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small cell lung cancer (GALAXY-2). J Thorac Oncol. 2017;12:S4, abstract PL03.9.
   Google Scholar
• Shapiro GI, Kwak E, Dezube BJ, et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:87–97.
   PubMed Web of Science ®Google Scholar
• Do K, Speranza G, Chang LC, et al. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs. 2015;33:921–930.
   PubMed Web of Science ®Google Scholar
• Isambert N, Delord JP, Soria JC, et al. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase. Ann Oncology. 2015;26:1005–1011.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28:4953–4960.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. IPI-504 in NSCLC Patients With ALK Translocations (NCT01228435). [cited 2017 Jan 11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01228435?term=ipi-504+and+lung+cancer&rank=4&sect=X70156
   Google Scholar
• Garon EB, Moran T, Barlesi F, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30:suppl, ASCO abstract 7543.
   Google Scholar
• Johnson ML, Yu HA, Hart EM, et al. Phase I/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33:1666–1673.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Costa DB, Huberman MS, et al. Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions. J Clin Oncol. 2015;33:suppl, ASCO abstract 8015.
   Google Scholar
• Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19:3068–3077.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Yu HA, Stephens D, et al. A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers. J Clin Oncol. 2015;33:suppl, abstract 8064.
   Web of Science ®Google Scholar
• Chi KN, Yu EY, Jacobs C, et al. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann Oncology. 2016;27:1116–1122.
   PubMed Web of Science ®Google Scholar
• Shipley DL, Waterhouse D, Jones S, et al. The Spruce clinical trial: double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer. J Clin Oncol. 2016;34:suppl, abstract 9092.
   Google Scholar
• Krause SW, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res. 2004;10:3699–3707.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Bhattacharya S, Socinski MA, et al. HSP90 inhibitors in lung cancer: promise still unfulfilled. Clin Adv Hematol Oncol. 2016;14:346–356. .
   PubMed Web of Science ®Google Scholar
• Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–6501.
   PubMed Web of Science ®Google Scholar
• Vermes K. Vernalis PLC (VNLPY.PK) stumbles as novartis AG (NVS) abandons work on AUY922 2014. [cited 2016 Oct 27.]. Available from: http://www.biospace.com/News/vernalis-plc-stumbles-as-novartis-ag-abandons-work/358835
   Google Scholar
• Luminespib (AUY922). [cited 2017 Jan 13]. Available from: http://www.vernalis.com/nce-pipeline/oncology/auy922
   Google Scholar
• Wang H, Zhao L, Zhu LT, et al. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1alpha and glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog. 2014;53(Suppl 1):E107–E118.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zheng T, Song R, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology. 2013;57:1847–1857.
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Park W, Wen J, et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis. 2013;16:903–917.
   PubMed Web of Science ®Google Scholar
• Rademakers SE, Lok J, van der Kogel AJ, et al. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 2011;11:167.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877–885.
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Haarberg HE, Wood E, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012;18:2502–2514.
   PubMed Web of Science ®Google Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA. 2009;106:8368–8373.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Zaric B, Ceric T, et al. Galaxy-2 trial (NCT01798485): a randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma. J Clin Oncol. 2014;32:5s. Suppl, abstract TPS8118.
   PubMed Web of Science ®Google Scholar
• Business Wire. Synta announces termination for futility of ganetespib phase 3 GALAXY-2 trial in lung cancer 2015. [cited 2016 Oct 27]. Available from: http://www.businesswire.com/news/home/20151020006900/en/Synta-Announces-Termination-Futility-Ganetespib-Phase-3.
   Google Scholar
• Courtin A, Smyth T, Hearn K, et al. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. Br J Cancer. 2016;115:1069–1077. .
   PubMed Web of Science ®Google Scholar
• Baylot V, Andrieu C, Katsogiannou M, et al. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011;2:e221.
   PubMed Web of Science ®Google Scholar
• Schmid P, Muthukumar D, Blackhall F, et al. Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: design of the Cedar study. J Clin Oncol. 2015;33:suppl, abstract TPS8111.
   PubMed Web of Science ®Google Scholar
• Botzler C, Li G, Issels RD, et al. Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response. Cell Stress Chaperones. 1998;3:6–11.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pfister K, Gehrmann M, et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones. 2001;6:337–344.
   PubMed Web of Science ®Google Scholar
• Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res. 2000;6:3312–3318.
   PubMed Web of Science ®Google Scholar
• Wen W, Liu W, Shao Y, et al. VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines. Exp Biol Med (Maywood). 2014;239:638–645.
   PubMed Web of Science ®Google Scholar
• Yoon T, Kang GY, Han AR, et al. 2,4-Bis(4-hydroxybenzyl)phenol inhibits heat shock transcription factor 1 and sensitizes lung cancer cells to conventional anticancer modalities. J Nat Prod. 2014;77:1123–1129.
   PubMed Web of Science ®Google Scholar
• Webber PJ, Park C, Qui M, et al. Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. Oncoscience. 2015;2:765–776.
   PubMedGoogle Scholar
• Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008;15:2702–2717.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Z, Qi X, et al. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90. Oncotarget. 2015;6:5263–5274.
   PubMed Web of Science ®Google Scholar
• McDowell CL, Bryan Sutton R, Obermann WM. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol. 2009;45:310–314.
   PubMed Web of Science ®Google Scholar
• Roman D, VerHoeve J, Schadt H, et al. Ocular toxicity of AUY922 in pigmented and albino rats. Toxicol Appl Pharmacol. 2016;309:55–62.
   PubMed Web of Science ®Google Scholar
• Ohkubo S, Kodama Y, Muraoka H, et al. TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol Cancer Ther. 2015;14:14–22.
   PubMed Web of Science ®Google Scholar
• Proia DA, Smith DL, Zhang J, et al. HSP90 inhibitor-SN-38 conjugate strategy for targeted delivery of topoisomerase I inhibitor to tumors. Mol Cancer Ther. 2015;14:2422–2432.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu H, Diao L, et al. Hsp90 inhibitor ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiation. Clin Cancer Res. 2016;22:5876–5886.
   PubMed Web of Science ®Google Scholar
• Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013;3:430–443.
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Yamada T, Nanjo S, et al. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 2014;5:4920–4928.
   PubMed Web of Science ®Google Scholar
• Fogliatto G, Gianellini L, Brasca MG, et al. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases. Clin Cancer Res. 2013;19:3520–3532. .
   PubMed Web of Science ®Google Scholar